FDA Panel To Review Atritech’s Watchman Stroke-Prevention Device
This article was originally published in The Gray Sheet
Executive Summary
FDA's Circulatory System Devices panel will meet April 23 to review a PMA for Atritech's Watchman minimally invasive stroke-prevention device for patients with atrial fibrillation, according to the company
You may also be interested in...
Panel Endorses Atritech Watchman Stroke-Prevention Device In Close Vote
An FDA advisory committee narrowly elected to recommend approval of Atritech's Watchman minimally invasive stroke-prevention device for atrial fibrillation patients, overcoming doubts about the size of the device's pivotal trial
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.